Craniofacial consequences of high-dose zoledronic acid injections in onco-pediatric patients

2013 ◽  
Author(s):  
Frederic Lezot ◽  
Julie Chesneau ◽  
Severine Battaglia ◽  
Regis Brion ◽  
Jean-Christophe Farges ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Pediatric Patients ◽  
High Dose

Craniofacial consequences of high dose zoledronic acid injections in onco-pediatric patients

2013 ◽  
Author(s):  
Lezot Frederic ◽  
Chesneau Julie ◽  
Battaglia Severine ◽  
Brion Regis ◽  
Farges Jean-Christophe ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Pediatric Patients ◽  
High Dose

New Therapeutic Approach to Reduce Methotrexate Toxicity after High-Dose Chemotherapy in a Child with Acute Lymphocytic Leukemia: Efficacy and Safety of Hemoadsorption with HA-230 Adsorber

2021 ◽  
pp. 1-5
Author(s):  
Vitaliy Sazonov ◽  
Zaure Tobylbayeva ◽  
Askhat Saparov ◽  
Bolatbek Jubaniyazov ◽  
Samat Issakov ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Pediatric Patients ◽  
High Dose Chemotherapy ◽  
The Body ◽  
Lymphocytic Leukemia ◽  
High Dose ◽  
Successful Implementation ◽  
Efficacy And Safety ◽  
Related Complication ◽  
Dose Methotrexate

Background: High-dose methotrexate (HDMTX) is likely to cause a number of side effects and manifest itself as hepatotoxicity, nephrotoxicity, mucositis, and neurotoxicity. A several studies demonstrated the efficacy of extracorporeal detoxification methods such as plasma exchange, hemodialysis (HD), HD filtration, and hemoperfusion for the treatment of MTX delayed clearance. However, none of the existing methods as effective as expected and limited for general implementation due to a procedure-related complication. Case Report: Here, we report a successful implementation of HA-230 hemoadsorption procedure to remove cumulated MTX from the body and reduce its toxicity in a child with ALL after high-dose chemotherapy. Results and Conclusion: Based on our results, single-hemoadsorption procedure with the HA-230 adsorber in case of delayed methotrexate clearance was safe and well-tolerated in a pediatric patient with ALL and would significantly improve the patient’s condition. Further studies need to demonstrate its safety and efficacy in a large number of pediatric patients.

scholarly journals Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis

2015 ◽  
Vol 8 (8) ◽  
pp. 20
Author(s):  
Abdulmoein E. Al-Agha ◽  
Talal A. Shaikhain ◽  
Abdullah A. Ashour
Keyword(s):  
Zoledronic Acid ◽  
Children And Adolescents ◽  
Pediatric Patients ◽  
Systemic Disease ◽  
Laboratory Data ◽  
University Hospital ◽  
Secondary Osteoporosis ◽  
Fracture Rate ◽  
Acid Therapy ◽  
Positive Effects

<p class="NormalWeb"><strong>BACKGROUND/AIM:</strong> Osteoporosis is a systemic disease characterized by decreased bone density and increased tendency to develop fractures. Osteoporosis in children and adolescents is a rare disease usually secondary to Medical conditions or medications given to children. The condition affects normal bone growth and development and carries with it multiple morbidities (physical and psychological) if not corrected promptly. This study aims to share our experience with Zoledronic Acid Therapy in Pediatric patients with secondary osteoporosis.</p><p class="NormalWeb"><strong>METHOD:</strong> A retrospective study which included 46 patients aged 3 to 18 years. All patients received specific doses of Zoledronic acid and were followed up at King Abdulaziz University Hospital (KAUH) in Jeddah, Saudi Arabia. Clinical and laboratory data were collected for each patient from their files. Adverse events were also recorded.</p><p class="NormalWeb"><strong>RESULTS:</strong> The use of Zoledronic Acid in children and adolescents appears to be statically significant reduce fracture rate (p=0.005), bone turnover markers (Osteocalcin p= 0.003, CTX p= 0.008) and pain frequency in symptomatic individuals (p=0.000). Careful selection of cases is required to provide maximum benefits compared to risks associated with therapy.</p><p class="NormalWeb"><strong>CONCLUSION:</strong> This study demonstrates that Zoledronic acid has positive effects on clinical outcome and bone marker level as well as quality of life for Pediatric patients with Osteoporosis and their families, with no long-term side effects.</p>

scholarly journals Lacosamide-Induced Dyskinesia in Children With Intractable Epilepsy

2020 ◽  
Vol 35 (10) ◽  
pp. 662-666
Author(s):  
Nadine Madani ◽  
Jennifer A. O’Malley ◽  
Brenda E. Porter ◽  
Fiona M. Baumer
Keyword(s):  
Upper Extremity ◽  
Pediatric Patients ◽  
Focal Epilepsy ◽  
Intractable Epilepsy ◽  
High Dose ◽  
Drug Induced ◽  
Potential Side Effect ◽  
Increased Risk ◽  
The Face ◽  
Dose Dependent

Lacosamide, an antiepileptic drug prescribed for children with refractory focal epilepsy, is generally well tolerated, with dose-dependent adverse effects. We describe 4 children who developed a movement disorder in conjunction with the initiation and/or uptitration of lacosamide. Three patients developed dyskinesias involving the face or upper extremity whereas the fourth had substantial worsening of chronic facial tics. The patients all had histories suggestive of opercular dysfunction: 3 had seizure semiologies including hypersalivation, facial and upper extremity clonus while the fourth underwent resection of polymicrogyria involving the opercula. Onset, severity, and resolution of dyskinesias correlated with lacosamide dosing. These cases suggest that pediatric patients with dysfunction of the opercular cortex are at increased risk for developing drug-induced dyskinesias on high-dose lacosamide therapy. Practitioners should be aware of this potential side effect and consider weaning lacosamide or video electroencephalography (EEG) for differential diagnosis, particularly in pediatric patients with underlying opercular dysfunction.

Sign in / Sign up

Export Citation Format

Share Document